Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Eur J Haematol
    December 2026
  1. GAO L, Nguyen D, White V, Livingston PM, et al
    Economic Burden of Chronic Lymphocytic Leukaemia in Australia.
    Eur J Haematol. 2026;117:1541-1551.
    >> Share

    November 2026
  2. KJAER CW, Sorum ME, Muller K, Weischendorff S, et al
    Reply to: "Interpreting the Association Between Plasma Citrulline and Bloodstream Infection in Pediatric Acute Myeloid Leukemia".
    Eur J Haematol. 2026 Nov 4. doi: 10.1111/ejh.70352.
    >> Share

  3. STEINER L, Silva-Bermudez LS, Ghazal M, Abba M, et al
    Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.
    Eur J Haematol. 2026;117:1358-1368.
    >> Share

  4. HU J, Shuai X, Guo Y, Gong Y, et al
    Prognostic Validation of IPSS-M Versus ELN 2022/2024 in MDS/AML Patients: A Survival and Treatment Response Analysis.
    Eur J Haematol. 2026;117:1309-1317.
    >> Share

  5. MA Y, Jiang Y, Wang L, Cheng Y, et al
    ARHGEF2::JAK2 Fusion Drives Leukemogenesis via CCNB1-Dependent Signaling.
    Eur J Haematol. 2026;117:1238-1248.
    >> Share

    October 2026
  6. ASLAN M, Yilmaz E
    Interpreting the Association Between Plasma Citrulline and Bloodstream Infection in Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Oct 13. doi: 10.1111/ejh.70341.
    >> Share

  7. MILOJKOVIC D, Cross NCP, Desai K, Frewin K, et al
    Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.
    Eur J Haematol. 2026;117:1072-1080.
    >> Share

  8. MARTINO EA, Caserta S, Vigna E, Cutrona G, et al
    To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.
    Eur J Haematol. 2026;117:750-766.
    >> Share

    September 2026
  9. TATAR D, Yilmaz E, Ozer NK
    Comment on Sakthivel Et al., "Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta-Analysis".
    Eur J Haematol. 2026 Sep 25. doi: 10.1111/ejh.70325.
    >> Share

  10. DAMPMANN M, Flossdorf S, Keyl J, Leitner T, et al
    Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany-A Multi-Center Analysis.
    Eur J Haematol. 2026 Sep 11. doi: 10.1111/ejh.70319.
    >> Share

  11. FORGHIERI F, Cordella S, Lazzarotto D, Annunziata M, et al
    Clinical Outcomes of Younger Adults With Philadelphia-Negative Acute Lymphoblastic Leukemia, Treated With A Pediatric-Like Regimen Based on the GIMEMA LAL1308 Protocol. A Campus ALL Study.
    Eur J Haematol. 2026 Sep 8. doi: 10.1111/ejh.70317.
    >> Share

  12. BRINK M, van der Spek AC, Doorduijn JK, de Heer K, et al
    Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.
    Eur J Haematol. 2026 Sep 4. doi: 10.1111/ejh.70312.
    >> Share

  13. ALBUQUERQUE TM, Sousa AVL, Rollo G, Adriano FKMS, et al
    Surgical Aspects of Patients With Leukemic Testicular Infiltration.
    Eur J Haematol. 2026;117:543-547.
    >> Share

    August 2026
  14. ORIQUAT G, Al-Hasnaawei S, Mousa HM, Malathi H, et al
    Extracellular Vesicle-Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges.
    Eur J Haematol. 2026 Aug 31. doi: 10.1111/ejh.70308.
    >> Share

  15. HOFSTETTER L, Buchrits S, Sherban A, Sternbach N, et al
    Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.
    Eur J Haematol. 2026 Aug 27. doi: 10.1111/ejh.70300.
    >> Share

  16. FIORENZO S, Elsa P, Alessandro S, Mario P, et al
    Long-Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    Eur J Haematol. 2026 Aug 14. doi: 10.1111/ejh.70292.
    >> Share

  17. MOLICA S
    Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia: Insights From EHA 2026.
    Eur J Haematol. 2026 Aug 5. doi: 10.1111/ejh.70288.
    >> Share

  18. KENNEDY VE, Peretz CAC, Koh A, Tran E, et al
    Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.
    Eur J Haematol. 2026;117:501-503.
    >> Share

  19. MARTINO EA, Chiarenza A, Mancuso S, Rossi M, et al
    Regional Standardization of CLL Management: Results of a Delphi Consensus Process.
    Eur J Haematol. 2026;117:442-447.
    >> Share

  20. MARTINO EA, Caserta S, Vigna E, Bruzzese A, et al
    From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
    Eur J Haematol. 2026;117:305-319.
    >> Share

  21. KUTSCH N, Ligtvoet R, Robrecht S, Linde H, et al
    Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.
    Eur J Haematol. 2026;117:351-357.
    >> Share

  22. MOLICA S, Lucignano M, Villa MR, Mettivier L, et al
    Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks.
    Eur J Haematol. 2026;117:366-374.
    >> Share

    July 2026
  23. TAKAOKA K, Mott S, Yodsuwan R, Saowapa S, et al
    KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations.
    Eur J Haematol. 2026 Jul 24. doi: 10.1111/ejh.70270.
    >> Share

  24. RUSSO S, Capodanno I, Tiribelli M, Miggiano MC, et al
    Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real-Life Survey Within the Italian Chronic Myeloid Leukemia Network.
    Eur J Haematol. 2026 Jul 22. doi: 10.1111/ejh.70268.
    >> Share

  25. KJAER CW, Sorum ME, De Pietri S, Moser C, et al
    Pronounced Reductions in Plasma Citrulline Indicate Severe Intestinal Mucosal Barrier Injury During Induction Therapy for Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Jul 17. doi: 10.1111/ejh.70267.
    >> Share

  26. WANG Y, Xiao R, Huang X, Xiao Y, et al
    Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia.
    Eur J Haematol. 2026 Jul 13. doi: 10.1111/ejh.70264.
    >> Share

  27. MOLICA S
    Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship Perspective.
    Eur J Haematol. 2026 Jul 12. doi: 10.1111/ejh.70265.
    >> Share

    June 2026
  28. MAY M, Limon De la Rosa N, Duarte C, Boosma G, et al
    Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia.
    Eur J Haematol. 2026 Jun 29. doi: 10.1111/ejh.70251.
    >> Share

  29. CHAOUI D, Stocker N
    Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged >/= 80 Years.
    Eur J Haematol. 2026 Jun 22. doi: 10.1111/ejh.70248.
    >> Share

  30. SKUDAR S
    Dynamic Frailty Assessment in Older Adults With Acute Myeloid Leukemia: From Treatment Eligibility to Treatment Adaptation.
    Eur J Haematol. 2026 Jun 15. doi: 10.1111/ejh.70243.
    >> Share

  31. BISCHOF L, Egger-Heidrich K, Schneider M, Friedrich G, et al
    Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.
    Eur J Haematol. 2026;116:937-942.
    >> Share

  32. EHLERS LH, Levin MD, van der Klift M, Jensen MB, et al
    Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naive Fit Patients With CLL Without TP53 Aberrations.
    Eur J Haematol. 2026;116:873-882.
    >> Share

  33. BATYRBEKOVA N, Landtblom AR, Hultcrantz M, Szulkin R, et al
    Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.
    Eur J Haematol. 2026;116:850-862.
    >> Share

    May 2026
  34. BRUZZESE A, Martino EA, Caserta S, Alvaro ME, et al
    Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment.
    Eur J Haematol. 2026 May 25. doi: 10.1111/ejh.70223.
    >> Share

  35. SALAH AN, Mansour RM, El-Sayyad GS, Moustafa HAM, et al
    Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia.
    Eur J Haematol. 2026 May 22. doi: 10.1111/ejh.70230.
    >> Share

  36. OU W, Yu Y, Zhu X, Jiang J, et al
    Combined Early Steroid Response and MRD Improve Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: The CCCG-ALL-2015 Study.
    Eur J Haematol. 2026 May 18. doi: 10.1111/ejh.70222.
    >> Share

  37. UCHIDA Y, Tateo S, Wakao M, Shinchi H, et al
    Development of Chimeric Antigen Receptor-Modified NK Cells for the Immunotherapy of Adult T-Cell Leukemia/Lymphoma.
    Eur J Haematol. 2026 May 3. doi: 10.1111/ejh.70199.
    >> Share

  38. ISHIKAWA C, Mori N
    Role of Nek2 and Hec1 in HTLV-1-Infected T-Cell Lines.
    Eur J Haematol. 2026;116:635-645.
    >> Share

  39. WU N, Kong J, Lv M, Mo XD, et al
    Bridging With Chimeric Antigen Receptor T-Cell Therapy or Chemotherapy to Allo-HSCT in B-ALL: A Comparison of Treatment Complications and Survival.
    Eur J Haematol. 2026;116:615-624.
    >> Share

    April 2026
  40. SONG L, Wei X, Zhai Z, Wang A, et al
    Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Apr 21. doi: 10.1111/ejh.70164.
    >> Share

  41. CASERTA S, Martino EA, Lofaro D, Vigna E, et al
    First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.
    Eur J Haematol. 2026 Apr 14. doi: 10.1111/ejh.70191.
    >> Share

  42. BRUZZESE A, Vigna E, Martino EA, Caserta S, et al
    Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
    Eur J Haematol. 2026 Apr 2. doi: 10.1111/ejh.70186.
    >> Share

    March 2026
  43. GOULARTE MN, Miyamoto MH, de Lacerda MP
    Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single-Arm Meta-Analysis.
    Eur J Haematol. 2026 Mar 25. doi: 10.1111/ejh.70175.
    >> Share

  44. BRUZZESE A, Vigna E, Martino EA, Caserta S, et al
    Ph-Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs.
    Eur J Haematol. 2026 Mar 15. doi: 10.1111/ejh.70169.
    >> Share

  45. MOLICA S, Allsup D
    Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.
    Eur J Haematol. 2026 Mar 12. doi: 10.1111/ejh.70160.
    >> Share

  46. MESSORI A
    Updating Efficacy of First-Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab.
    Eur J Haematol. 2026 Mar 2. doi: 10.1111/ejh.70150.
    >> Share

    February 2026
  47. GAIDANO G, Danesi R
    Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives.
    Eur J Haematol. 2026 Feb 24. doi: 10.1111/ejh.70144.
    >> Share

  48. TIDSWELL R, Owen C, Shafey M, Perry S, et al
    Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Eur J Haematol. 2026 Feb 16. doi: 10.1111/ejh.70137.
    >> Share

    January 2026
  49. SABBAGH C
    Distribution of ABO/Rh Blood Types Across Childhood Leukemia Subtypes: A Retrospective Cohort Study of 540 Pediatric Patients.
    Eur J Haematol. 2026 Jan 30. doi: 10.1111/ejh.70127.
    >> Share

  50. MAHESWARAN S, Gordon CD, Chen EC, Patel SA, et al
    Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia.
    Eur J Haematol. 2026 Jan 23. doi: 10.1111/ejh.70120.
    >> Share

  51. SEKAR AJ, Sakthivel S, Valsala Gopalakrishnan A, Vashishth R, et al
    An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies.
    Eur J Haematol. 2026 Jan 13. doi: 10.1111/ejh.70110.
    >> Share

    December 2025
  52. NOURBAKHSH SMK, Valadkhani C, Safaei H
    Clinical and Laboratory Indicators of Pediatric Leukemia and Neuroblastoma in Musculoskeletal Presentations: A Retrospective Study From a Resource-Limited Setting.
    Eur J Haematol. 2025 Dec 29. doi: 10.1111/ejh.70106.
    >> Share

  53. HO TN, Willard P, Murray GF, Liu L, et al
    Improvements in Real-World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment.
    Eur J Haematol. 2025 Dec 23. doi: 10.1111/ejh.70087.
    >> Share

  54. KASMI D, Bisegna ML, Carmosino I, Scalzulli E, et al
    Outpatient Versus Inpatient Azacitidine Plus Venetoclax Regimen in Elderly Acute Myeloid Leukemia: A Multicenter Retrospective Analysis.
    Eur J Haematol. 2025 Dec 21. doi: 10.1111/ejh.70102.
    >> Share

  55. SAKTHIVEL M, Katneni P, Nataraja RM, Pacilli M, et al
    Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta-Analysis.
    Eur J Haematol. 2025 Dec 15. doi: 10.1111/ejh.70080.
    >> Share

  56. CUNNINGHAM I, Fisher RA, Yang J, Guo Y, et al
    Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study.
    Eur J Haematol. 2025 Dec 10. doi: 10.1111/ejh.70051.
    >> Share

  57. TVEDT THA, Qvigstad C, Nezvalova-Henriksen K, Bergland BS, et al
    Three-Month Posttransplant Lipidomic Profile Reflects Acute GVHD but Not Chronic GVHD Risk in Allogeneic Stem Cell Recipients.
    Eur J Haematol. 2025;115:565-573.
    >> Share

    November 2025
  58. MARTINO EA, Caserta S, Vigna E, Bruzzese A, et al
    Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies.
    Eur J Haematol. 2025 Nov 25. doi: 10.1111/ejh.70065.
    >> Share

  59. VIGNA E, Bruzzese A, Mule A, Sucato G, et al
    Real-World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Nov 6. doi: 10.1111/ejh.70057.
    >> Share

    October 2025
  60. RONGJIE L, Lijuan Q, Bailing Z, Liyue K, et al
    Spontaneous Remission and Subsequent Relapse in Pediatric Acute Myeloid Leukemia (AML-M5): A Case Report and Literature Review.
    Eur J Haematol. 2025 Oct 29. doi: 10.1111/ejh.70044.
    >> Share

  61. VIGNA E, Bruzzese A, Martino EA, Corsonello A, et al
    Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.
    Eur J Haematol. 2025 Oct 29. doi: 10.1111/ejh.70058.
    >> Share

  62. OLIVA S, Molica S
    Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy.
    Eur J Haematol. 2025 Oct 21. doi: 10.1111/ejh.70047.
    >> Share

  63. LIEW-LITTORIN M, Deleskog-Spangberg L, Deneberg S, Janosi J, et al
    Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML-A Population-Based Study.
    Eur J Haematol. 2025;115:423-432.
    >> Share

    September 2025
  64. SRINIVASAN T, Mallik N, Sachdeva MUS, Bose P, et al
    CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T-Cell Acute Lymphoblastic Leukemia.
    Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70035.
    >> Share

  65. TOKUDA C, Iwasaki M, Kanda J, Kondo T, et al
    Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Sep 9. doi: 10.1111/ejh.70024.
    >> Share

  66. HANSEN MH, Gulmir R, Cedile O, Dahlmann SK, et al
    Performance of Rapid Clonotyping of Chronic Lymphocytic Leukemia Using Flongle Flow-Cell Nanopore Sequencing of IGH Rearrangements.
    Eur J Haematol. 2025 Sep 8. doi: 10.1111/ejh.70030.
    >> Share

    August 2025
  67. PALUMBO FE, Vetro C, Calafiore V, Duminuco A, et al
    Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement.
    Eur J Haematol. 2025 Aug 14. doi: 10.1111/ejh.70021.
    >> Share

  68. STEIDEL E, Orhan E, Rasche M, Pigazzi M, et al
    Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.
    Eur J Haematol. 2025 Aug 13. doi: 10.1111/ejh.70019.
    >> Share

  69. FENWARTH L, Podvin B, Vasseur L, Lebon D, et al
    Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles.
    Eur J Haematol. 2025;115:185-192.
    >> Share

  70. BAHRAMI HEZAVEH E, Yan J, Zhao D, Wangulu C, et al
    Genetic Landscape and Risk Stratification of AML With Hyperdiploid Karyotype.
    Eur J Haematol. 2025;115:165-175.
    >> Share

    July 2025
  71. MAHAMEED B, Sharf G, Tadmor T, Kleinstern G, et al
    Gender Disparities in Health-Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality.
    Eur J Haematol. 2025 Jul 31. doi: 10.1111/ejh.70017.
    >> Share

    June 2025
  72. LAGANA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Treatment Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse.
    Eur J Haematol. 2025 Jun 30. doi: 10.1111/ejh.70006.
    >> Share

  73. BRUZZESE A, Vigna E, Martino EA, Amodio N, et al
    Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.
    Eur J Haematol. 2025 Jun 23. doi: 10.1111/ejh.70000.
    >> Share

  74. LI Y, Liu X, Li W, Hou L, et al
    Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14442.
    >> Share

  75. KRUSZEWSKI M, Schmoor C, Berg T, Rehman UU, et al
    Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14426.
    >> Share

  76. TADMOR T, Melamed G, Alapi H, Rokach L, et al
    CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy.
    Eur J Haematol. 2025;114:1011-1019.
    >> Share

    May 2025
  77. ALNUGHMUSH A, Alyamany R, Remberger M, Pasic I, et al
    Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.
    Eur J Haematol. 2025 May 28. doi: 10.1111/ejh.14438.
    >> Share

  78. KOCKEROLS C, Valk PJM, Hogenbirk P, Geelen I, et al
    Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.
    Eur J Haematol. 2025;114:900-907.
    >> Share

    April 2025
  79. FRISCH A, Ganzel C, Ofran Y, Krayem B, et al
    Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
    Eur J Haematol. 2025;114:641-649.
    >> Share

    March 2025
  80. LOHRBERG M, Heber M, Ries L, Markus K, et al
    Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
    Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
    >> Share

  81. CHEN D, Cantu M, Siddon A, Weinberg OK, et al
    TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis.
    Eur J Haematol. 2025 Mar 28. doi: 10.1111/ejh.14421.
    >> Share

  82. POONSOMBUDLERT K, Yodsuwan R, Mott S, Crawford K, et al
    Effect of NPM1 Mutation Subtype and Co-Mutation Patterns on the Outcomes of Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Mar 19. doi: 10.1111/ejh.14415.
    >> Share

  83. ZHENG R, Gagan JR, Botten GA, Koduru P, et al
    Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment.
    Eur J Haematol. 2025 Mar 18. doi: 10.1111/ejh.14414.
    >> Share

  84. CHUNG C, Doan D
    Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy.
    Eur J Haematol. 2025 Mar 11. doi: 10.1111/ejh.14408.
    >> Share

  85. NAGAFUJI K, Ito Y, Miyamoto T, Eto T, et al
    Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG).
    Eur J Haematol. 2025 Mar 7. doi: 10.1111/ejh.14407.
    >> Share

  86. BRUZZESE A, Martino EA, Labanca C, Carida G, et al
    Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.
    Eur J Haematol. 2025 Mar 6. doi: 10.1111/ejh.14405.
    >> Share

  87. GHIMIRE B, Zimmer M, Donthireddy V
    TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges.
    Eur J Haematol. 2025 Mar 4. doi: 10.1111/ejh.14404.
    >> Share

    February 2025
  88. VEYHE SR, Hansen MH, Cedile O, Moller MB, et al
    A Case-Driven Multi-Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14397.
    >> Share

  89. CASTELLET H, Ramil G, Carricondo M, Onate G, et al
    Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14402.
    >> Share

  90. ROBAK T, Robak M, Majchrzak A, Krawczynska A, et al
    Atypical Hairy Cell Leukemia-The Current Status and Future Directions.
    Eur J Haematol. 2025 Feb 10. doi: 10.1111/ejh.14388.
    >> Share

  91. BENOIT TM, Bachofner A, Wolfensberger N, Zaugg-Berger Y, et al
    Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
    Eur J Haematol. 2025;114:315-324.
    >> Share

  92. BRESSER H, Schmoor C, Grishina O, Pfeifer D, et al
    Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
    Eur J Haematol. 2025;114:231-237.
    >> Share

    January 2025
  93. HYPPOLITO JE, Arcuri LJ, Vicente A, Farnese V, et al
    Central Nervous System Involvement in Chronic Lymphocytic Leukemia: A Case-Series.
    Eur J Haematol. 2025 Jan 31. doi: 10.1111/ejh.14389.
    >> Share

  94. YANG MM, Singh R, Haugen M, Duff A, et al
    Adherence to 6-Mercaptopurine (6-MP) and Habit Strength in Pediatric Acute Lymphoblastic Leukemia (ALL).
    Eur J Haematol. 2025 Jan 20. doi: 10.1111/ejh.14386.
    >> Share

  95. ZALAPA-SOTO J, Rios-Olais FA, Chacon-Rangel LC, Mora-Canas A, et al
    Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.
    Eur J Haematol. 2025 Jan 7. doi: 10.1111/ejh.14381.
    >> Share

  96. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14383.
    >> Share

  97. BERTON G, Hospital MA, Garciaz S, Rouzaud C, et al
    Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14366.
    >> Share

  98. JENSEN ABH, Andersen HRP, Jensen ST, Jensen CF, et al
    Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study.
    Eur J Haematol. 2025;114:57-69.
    >> Share

    December 2024
  99. PUCKRIN R, Owen C, Peters A
    Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2024 Dec 27. doi: 10.1111/ejh.14376.
    >> Share

  100. TANG MW, Van der Tuin D, Aydin M, Heijmans J, et al
    Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14370.
    >> Share

  101. ROWE M, Babushok D, Carroll M, Carulli A, et al
    Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14371.
    >> Share

    November 2024
  102. MORT JF, Brighton D, DiBenedetto S, Wells L, et al
    Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 27. doi: 10.1111/ejh.14354.
    >> Share

  103. YALNIZ FF, Johnson A, Alnimer Y, Chahine Z, et al
    Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.
    Eur J Haematol. 2024 Nov 13. doi: 10.1111/ejh.14338.
    >> Share

  104. CHEN EY, Dahlen T, Stenke L, Bjorkholm M, et al
    Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 6. doi: 10.1111/ejh.14328.
    >> Share

  105. SMITH E, Atenafu EG, Bankar A, Chan S, et al
    Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
    Eur J Haematol. 2024;113:716-726.
    >> Share

    October 2024
  106. SHACHAM-ABULAFIA A, Volcheck Y, Ellis M, Shapira S, et al
    Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Oct 21. doi: 10.1111/ejh.14330.
    >> Share

  107. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
    Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14327.
    >> Share

    September 2024
  108. MURRAY GF, Bouligny IM, Ho T, Gor J, et al
    Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 24. doi: 10.1111/ejh.14308.
    >> Share

  109. STEINER N, Massoud R, Richter J, Perekhrestenko T, et al
    Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
    Eur J Haematol. 2024 Sep 19. doi: 10.1111/ejh.14305.
    >> Share

  110. BUCELLI C, Capodanno I, Miggiano MC, Cavazzini F, et al
    Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
    Eur J Haematol. 2024 Sep 12. doi: 10.1111/ejh.14299.
    >> Share

  111. WILLE K, Dumke M, Wilsdorf N, Sadjadian P, et al
    Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 9. doi: 10.1111/ejh.14302.
    >> Share

  112. ISHIKAWA C, Mori N
    A New Strategy for Adult T-Cell Leukemia Treatment Targeting Glycogen Synthase Kinase-3beta.
    Eur J Haematol. 2024 Sep 6. doi: 10.1111/ejh.14300.
    >> Share

  113. LIN S, Liao N, Li X, Yang L, et al
    Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
    Eur J Haematol. 2024;113:357-370.
    >> Share

    August 2024
  114. SOUA A, Gilhodes J, Iat A, Hicheri Y, et al
    Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
    Eur J Haematol. 2024 Aug 11. doi: 10.1111/ejh.14290.
    >> Share

    July 2024
  115. RANTI J, Pudas H, Ranta M, Tuominen S, et al
    Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records.
    Eur J Haematol. 2024 Jul 29. doi: 10.1111/ejh.14272.
    >> Share

  116. ACKER F, Chromik J, Tiedjen E, Wolf S, et al
    Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Eur J Haematol. 2024 Jul 18. doi: 10.1111/ejh.14278.
    >> Share

  117. KOCKEROLS C, Valk PJM, Janssen JJWM, Hogenbirk P, et al
    Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Eur J Haematol. 2024 Jul 12. doi: 10.1111/ejh.14271.
    >> Share

  118. LINES M, Kemper RM, Wallace J, Alexander T, et al
    Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
    Eur J Haematol. 2024 Jul 11. doi: 10.1111/ejh.14273.
    >> Share

  119. GUEUNING C, Lazaro E, Dupuy H, Leonard C, et al
    Characteristics of large granular lymphocyte leukemia associated with variable common immunodeficiency disorders: A study of 12 cases.
    Eur J Haematol. 2024 Jul 10. doi: 10.1111/ejh.14265.
    >> Share

    June 2024
  120. SKIPPER MT, Birkebaek N, Jensen RB, Rank CU, et al
    Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
    Eur J Haematol. 2024;112:944-956.
    >> Share

  121. GERHARDT A, Dorfel S, Schulz H, Schlag R, et al
    Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
    Eur J Haematol. 2024;112:927-937.
    >> Share

  122. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
    Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
    Eur J Haematol. 2024;112:984-987.
    >> Share

    May 2024
  123. TAGHILOO S, Asgarian-Omran H
    Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
    Eur J Haematol. 2024 May 2. doi: 10.1111/ejh.14224.
    >> Share

  124. KUTSCH N, Giza A, Robrecht S, Stumpf J, et al
    Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
    Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220.
    >> Share

    April 2024
  125. AFTANDILIAN C, Bito XR, Berman D, Zhang A, et al
    Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
    Eur J Haematol. 2024 Apr 24. doi: 10.1111/ejh.14216.
    >> Share

  126. MARRA JD, Galli E, Giammarco S, Metafuni E, et al
    CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
    Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217.
    >> Share

  127. MIKLOS E, Oliver TP, Adam K, Eva K, et al
    Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
    Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14213.
    >> Share

  128. GRONLUND JK, Veigaard C, Juhl-Christensen C, Skou AS, et al
    Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
    Eur J Haematol. 2024;112:601-610.
    >> Share

  129. DELANOTE V, Callens R, Vogelaers D, Deeren D, et al
    Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
    Eur J Haematol. 2024;112:627-632.
    >> Share

  130. PETIT C, Saillard C, Mohty B, Hicheri Y, et al
    Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Eur J Haematol. 2024;112:530-537.
    >> Share

  131. ISHIKAWA C, Mori N
    Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Eur J Haematol. 2024 Apr 1. doi: 10.1111/ejh.14209.
    >> Share

    March 2024
  132. POONSOMBUDLERT K, Mott S, Miller B, Dhakal P, et al
    Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
    Eur J Haematol. 2024 Mar 21. doi: 10.1111/ejh.14199.
    >> Share

  133. ZHANG X, Zhang K, Zhang J, Chang W, et al
    DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
    Eur J Haematol. 2024;112:439-449.
    >> Share

  134. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    >> Share

    February 2024
  135. GAO J, Santana-Santos L, Fu L, Alvey E, et al
    Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
    Eur J Haematol. 2024 Feb 22. doi: 10.1111/ejh.14192.
    >> Share

  136. SUN Y, Zhu G, Zhong H
    Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Eur J Haematol. 2024 Feb 11. doi: 10.1111/ejh.14187.
    >> Share

  137. MELLINGHOFF SC, Robrecht S, Sprute R, Mayer L, et al
    Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2024 Feb 4. doi: 10.1111/ejh.14170.
    >> Share

  138. INFANTE JB, Esteves GV, Raposo J, de Lacerda JF, et al
    Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients.
    Eur J Haematol. 2024 Feb 2. doi: 10.1111/ejh.14177.
    >> Share

  139. SEVOYAN A, Mekinian A, Chermat F, Ades L, et al
    MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
    Eur J Haematol. 2024;112:296-300.
    >> Share

    January 2024
  140. WIESEN MHJ, Stemler J, Fietz C, Joisten C, et al
    Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 31. doi: 10.1111/ejh.14178.
    >> Share

  141. PODGORICA M, Drivet E, Viken JK, Richman A, et al
    Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis.
    Eur J Haematol. 2024 Jan 8. doi: 10.1111/ejh.14164.
    >> Share

  142. MOYEN TB, Tomaz V, Campregher PV
    Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14158.
    >> Share

  143. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    >> Share

  144. WANG XY, Bian MR, Lin GQ, Yu L, et al
    Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Eur J Haematol. 2024;112:83-93.
    >> Share

  145. JI Q, Wu X, Zhang Y, Zeng L, et al
    Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
    Eur J Haematol. 2024;112:75-82.
    >> Share

  146. KHAN AN, Asija S, Pendhari J, Purwar R, et al
    CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Eur J Haematol. 2024;112:6-18.
    >> Share

    December 2023
  147. TAMEFUSA K, Ochi M, Ishida H, Shiwaku T, et al
    Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14162.
    >> Share

  148. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    >> Share

  149. NEUMANN MA, Nieper P, Simon F, Shimabukuro-Vornhagen A, et al
    A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
    Eur J Haematol. 2023 Dec 17. doi: 10.1111/ejh.14153.
    >> Share

  150. COSTA A, Carmosino I, Scalzulli E, Minotti C, et al
    Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.
    Eur J Haematol. 2023 Dec 14. doi: 10.1111/ejh.14155.
    >> Share

  151. LAGANA A, Pepe S, Scalzulli E, Carmosino I, et al
    One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.
    Eur J Haematol. 2023;111:970-972.
    >> Share

    November 2023
  152. NEVEJAN L, Labarque V, Boeckx N
    Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
    Eur J Haematol. 2023 Nov 20. doi: 10.1111/ejh.14137.
    >> Share

  153. LEE BJ, Griffin SP, Doh J, Chan A, et al
    HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Nov 6. doi: 10.1111/ejh.14125.
    >> Share

    October 2023
  154. SEGHATOL-ESLAMI VC, Cook EW 3rd, Sharafeldin N, Wolfson J, et al
    Adaptive functioning and academic achievement in pediatric survivors of acute lymphoblastic leukemia: Associations with executive functioning, socioeconomic status, and academic support.
    Eur J Haematol. 2023 Oct 5. doi: 10.1111/ejh.14112.
    >> Share

  155. KRISTENSEN DT, Brondum RF, Orskov AD, Marcher CW, et al
    Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.
    Eur J Haematol. 2023;111:573-582.
    >> Share

  156. MIYAJIMA T, Onozawa M, Yoshida S, Miyashita N, et al
    Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Eur J Haematol. 2023;111:620-627.
    >> Share

  157. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    >> Share

    September 2023
  158. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    >> Share

  159. KOCKEROLS C, Valk PJM, Blijlevens NMA, Cornelissen JJ, et al
    BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
    Eur J Haematol. 2023 Sep 20. doi: 10.1111/ejh.14107.
    >> Share

  160. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    >> Share

  161. ZARLING LC, Stevenson PA, Soma LA, Martino CH, et al
    Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 5. doi: 10.1111/ejh.14089.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016